Sales of Novo Nordisk's Wegovy are off to a good start in 2023
Sales of Novo Nordisk’s most recent obesity drug, Wegovy, have picked up speed in the US. Total prescriptions in 2023’s first week totaled 29,879 compared to 18,839 the week before, show figures cited by investment bank Citi from market analysis firm IQVIA, as reported by Danish business daily Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly predicts possible launch of obesity drug in 2023
For subscribers